UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q /A

(Mark One)

þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the period ended June 30, 2010

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NO. 333-134987

TETRAGENEX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE		22-3781895
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

6901 Jericho Turnpike, Suite 221

Syosset, NY 11791

(Address of principal executive offices)(Zip Code)

(516) 855-4425

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

þYes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer 	Accelerated filer 
Non-accelerated filer 	Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes þNo

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Check whether the registrant filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. Yes þNo

Number of shares outstanding of Issuer’s common stock, $0.001 par value, outstanding on August 15, 2010: 18,798,348

TABLE OF CONTENTS

PART I: FINANCIAL INFORMATION		1
ITEM 1.	FINANCIAL STATEMENTS	1
ITEM 2.	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	2
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	5
ITEM 4.	CONTROLS AND PROCEDURES	5
PART II: OTHER INFORMATION		6
ITEM 1.	LEGAL PROCEEDINGS	6
ITEM 1A.	RISK FACTORS	6
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	6
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	7
ITEM 4.	REMOVED	7
ITEM 5.	OTHER INFORMATION	7
ITEM 6.	EXHIBITS	7
SIGNATURES		8

PART I: FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

Index to Financial Statements

	Page
Unaudited Condensed Balance Sheet as of June 30 , 2010 and Audited Balance Sheet as of December 31, 2009	F-1
Unaudited Condensed Statement of Operations for the Three and Six Month Periods ending June 30, 2010 and 2009	F-2
Unaudited Condensed Statement of Cash Flows for the Six-Month Periods Ended June 30, 2010 and 2009	F-3
Notes to Unaudited Condensed Financial Statements	F-4

TETRAGENEX PHARMACEUTICALS, INC.

BALANCE SHEET

		December			June
		31, 2009			30, 2010
					(unaudited)
ASSETS

Current assets
	Cash and cash equivalents	$	21,420		$	102,171
	Other Receivable		133,079			-
	Prepaid insurance and other current assets		4,034			11,356
			158,533			113,527

Property and equipment, net			4,933			3,318
Security Deposit			4,188			4,188
Patents, net			10,000			9,000

		$	177,654		$	130,033
LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities
	Notes payable		411,994			371,686
	Accounts payable and accrued expenses		2,860,516			3,210,968
	Accrued interest		63,556			85,871

	Total current liabilities		3,336,066			3,668,525
Long term liability
	Notes payable		50,000			85,000

	Total liabilities		3,386,066			3,753,525

Commitments and contingencies

Stockholders' equity
	Class A preferred stock - $.01 par value - 5,000,000
	15,926,126 and 18,798,348 shares issued and outstanding respectively		-			-
	Common stock - $.001 par value - 50,000,000 shares authorized
	15,926,126 shares issued and outstanding		15,926			18,798
	Additional paid-in capital		101,840,856			101,896,983
	Accumulated deficit		(105,065,194	)		(105,539,273	)

	Total stockholders' equity		(3,208,412	)		( 3,623,492	)

		$	177,654		$	130,033

The accompanying footnotes are an integral part of the financial statements.

F-1

TETRAGENEX PHARMACEUTICALS, INC.

STATEMENTS OF OPERATIONS

		Three months ended June 30,						Six months ended June 30,

		2010			2009			2010			2009
Revenue		(unaudited)						(unaudited)
	Contract revenue	$	-		$	-		$	-		$	-
			-			-			-			-

Operating expenses
	Research and development	$	-		$	4,900		$	(4,900	)	$	4,900
	Investment Expenses		7,500			-			7,500			-
	Compensation expense		162,962			776,641			331,853			820,997
	Travel		5,552			9,484			7,128			24,247
	General and administrative		26,505			137,519			60,160			164,868
	Professional fees		279			30,865			10,430			45,865
	Payroll taxes and employee benefits		7,290			16,619			18,455			33,848
	Consulting fees		1,500			2,780			2,500			5,963
	Rent and occupancy		12,868			7,372			25,420			18,781
	Depreciation and amortization		785			18,047			1,570			35,708

Loss before other income (expense)			( 225,241	)		(1,004,227	)		( 460,116	)		(1,155,177	)

Other income (expense)
	Loss on disposal of fixed asset		-			-			(1,045	)		-
	Relief from Liabilities		-			-			19,089			-
	Interest income and other		-			82			0			322
	Interest expense		( 13,531	)		(39,200	)		( 32,007	)		( 65,154	)

Loss before tax benefit			(238,772	)		(1,043,345	)		( 474,079	)		(1,220,009	)

Net loss		$	(238,772	)	$	(1,043,345	)	$	( 474,079	)	$	( 1,220,009	)


Basic and diluted net loss per share		$	(0.01	)	$	(0.07	)	$	(0.03	)	$	(0.08	)

Weighted average common shares outstanding			16,841,449			15,926,126			16,386,316			15,926,126

The accompanying footnotes are an integral part of the financial statements.

F-2

TETRAGENEX PHARMACEUTICALS, INC.

STATEMENTS OF CASH FLOWS

	Six months ended June 30,

	2010			2009
Cash flows from operating activities	(unaudited)
Net loss	$	( 474,079	)	$	(1,220,009	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		1,570			22,836
Amortization of Debt Discount		9,692			12,872
Loss on disposal of fixed asset		1,045			-
Stock & warrant compensation		9,000			-
Changes in operating assets and liabilities
Prepaid insurance and other current assets		(7,322	)		4,753
Other Receivable		133,079			-
Accounts payable and accrued expenses		350,451			861,450
Accrued interest payable		22,315			65,155

Net cash used in operating activities		45,751			(252,943	)

Cash flows from investing activities
Cash paid for equipment		-			(844	)
Patent Cost		-			(6,575	)

Net cash used in investing activities		-			(7,419	)

Cash flows from financing activities
Proceeds from notes payable		35,000			25,000
Proceeds form Sale of Common Stock		50,000			-
Payments on notes payable		(50,000	)

Net cash provided by financing activities		35,000			25,000

Net increase (decrease) in cash and cash equivalents		80,751			(235,362	)

Cash and cash equivalents, beginning of year		21,420			329,863

Cash and cash equivalents, end of period	$	102,171		$	94,501

Non Cash Transactions
Stock, options, and warants issued for compensation	$	1,500		$	-

The accompanying footnotes are an integral part of the financial statements.

F-3

Notes to the Financial Statements

1. THE COMPANY

Tetragenex Pharmaceuticals, Inc. (the “Company” or “Tetragenex”) is headquartered in Syosset NY, and is a wholly owned subsidiary of Innapharma, Inc. (“Innapharma”). Innapharma was founded in 1989 in the State of Delaware as a biotechnology company that has discovered and intends to commercialize proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases

Tetragenex has a platform of peptides which have shown activity in the treatment of CNS diseases. Nemifitide, the Company’s lead compound, was initially entered into human clinical trials in the late 1990’s. Over 12 clinical trials have been conducted with Nemifitide for various types of depression. Tetragenex believes that Nemifitide is active in refractory or treatment resistant patients. Treatment resistant patients are typically difficult to treat and normally don’t respond to other CNS treatments., Nemifitide has shown a rapid and robust onset of action with lasting benefits of approximately four months following treatment. Nemifitide is well tolerated, without any current evidence of significant side effects as compared to the current drugs that are used in the treatment of major depressive disorder.

Nemifitide is administered thru subcutaneous injection and is given intermittently with 6 to 9 doses over 1 to 2 weeks. Patients who respond tend to stay healthy for several months after the initial dosing regimen.

As a result of the difficult economic environment, the Company believes it is improbable that it will be able to obtain FDA approval for Nemifitide to be administered in the United States prior to the expiration of its patents in 2014. Therefore, the Company is seeking regulatory approval to sell Nemifitide in several Central American, Eastern European and Caribbean countries based on its current data. Patients will then be treated at centers located in those countries.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Going Concern and Liquidity

The financial statements of the Company have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company had income of $34,285 and loss of $1,106,807 for the years ended December 31, 2009 and 2008 respectively and a loss of $474,079 for the quarter ended June 30, 2010. In addition at June 30, 2010 the Company has a working capital deficiency of $3,538,490, current liabilities of approximately $3,668,525 and a deficiency in stockholder’s equity of $3,623,492 . As of June 30, 2010 the Company had less than twelve months working capital in the bank and its main source of funds has been private investments. These factors raise doubt about the Company’s ability to continue as a going concern. The Company’s low stock price and its continuing losses may make it difficult to obtain either equity or debt financing, and, there can be no assurances that additional financing which is necessary for the Company to continue its business will be available to the company on acceptable terms, or at all. The Company’s ability to continue its operations is dependent upon its ability to generate sufficient funds from financings to meet its obligations on a timely basis and to further develop and market its products.

The accompanying financial statements do not include any adjustments that might result from the outcome of these uncertainties.

F-4

Interim Financial Statements

Financial statements as of June 30, 2010, and for the six month periods ended June 30, 2010 and 2009, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. The interim condensed financial statements should be read in conjunction with the audited financial statements for the years ended December 31, 2009 and 2008 as appearing in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2010.

3. NOTES PAYABLE

During 2008 and into 2009 the Company raised $375,000 as part of a bridge loan. In exchange for the funds the Company issued promissory notes payable totaling $375,000 plus 12% interest per annum. The notes mature on the earlier of(a) the two year anniversary of their issue date, or (b) upon the closing of at least $2 million in funding. The promissory notes were accompanied by an aggregate of 1,500,000 warrants exercisable at $0.40 per share expiring in 2013. A discount of $4,814 and $58,597 was recorded in 2009 and 2008 respectively as a result of the warrants. The warrants were valued using the BlackScholes Method.

In January 2010 we issued a secured promissory note to one of our directors, with a principal face value of $85,000. The secured promissory note was issued in exchange for cash payments owed to the director in the amount of $85,000. The note carries interest at a rate of 12% per annum and matures on the two year anniversary of the issue date.

On January 11, 2010, the Company entered into a Settlement, Release and Compromise Agreement (the “Settlement Agreement”) with KBC Private Equity NV (“KBC”). Pursuant to the Settlement Agreement, in acknowledgement of the Company’s financial situation, KBC accepted $50,000 as settlement (the “Settlement”) for a $2,227,000 debt that the Company owed KBC, which included accrued interest of $345,922. Upon payment of the Settlement, KBC released its preferred equity interest in the Company’s intellectual property, as well as any other secured or unsecured claim it may have against the Company. As a result of the settlement the Company recorded a gain of $2,177,000 in 2010.

4. STOCK OPTIONS

All of the Company’s stock options vest immediately upon issuance. The stock options are not actively trading and the fair market value is not readily ascertainable, the options are taxable at the time of exercise as opposed to the time of their grant.

The following table presents information regarding weighted-average exercise price and weighted average remaining contractual life as of June 30, 2010 for all options currently outstanding.

F-5

	Options Outstanding and Exercisable
Exercise Price	Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Life
$1.00	11,838,253	$1.00	8.4

5. PROMISSORY NOTES/WARRANTS

During May, June and October 2008, the Company issued promissory notes carrying 12% interest per annum having an aggregate face value of $350,000, together with warrants to purchase an aggregate of 1,400,000 shares of the Company’s common stock at $0.40 per share, to seven individuals. The warrants expire 5 years from the date of issuance.

In April 2010 the Company signed a consulting agreement with a scientist to perform an animal study on Nemifitide. In lieu of cash compensation, the scientist was issued warrants to purchase 150,000 shares of the Company’s common stock at $0.03 per share expiring 5 years from issuance.

In May 2010, one accredited investor purchased 2,872,222 shares of common stock at $0.017 per share, or an aggregate of $50,000. The common stock was accompanied by Warrants to purchase 750,000 shares of common stock exercisable at $0.03 per share expiring 5 years from issuance.

The following table presents, for each of the following classes of warrants as determined by range of exercise price, information regarding warrants outstanding and weighted-average exercise price as of June 30, 2010.

	Warrants Outstanding
Range of Exercise Price	Number of Warrants	Weighted Average Exercise Price
$1.65	645,322	$1.65
$6.00	3,284,396	$6.00
$0.40	1,400,000	$0.40
$0.03	900,000	$0.03

6. COMMON STOCK TRANSACTIONS

At June 30, 2010, the Company had authorized 50,000,000 shares of common stock, $0.001 stated value. The following table represents the approximate allocation of reserved shares at June 30, 2010:

Type of Security	Amount Outstanding
Common Stock		18,798,348
Stock Options		11,838,253
Warrants		6,229,718
		36,866,319

F-6

7. LITIGATION

At June 30, 2010 the Company was not involved in any ongoing litigation.

8. RISKS AND UNCERTAINTIES

As reflected in the accompanying consolidated financial statements, the Company has incurred significant recurring losses from operations and negative operating cash flows, which have been financed primarily by proceeds from stock and debt issuances. As a result, the Company had an accumulated deficit of $105,539,273 and $105,065,194 at June 30, 2010 and December 31, 2009, respectively.

The Company is considering all strategic options which may provide working capital to fund its continuing business operations including equity offerings and debt financings; however; the Company can offer no assurance that it will be successful in identifying, obtaining or negotiating financing terms. If adequate funds are not available or are not available on terms acceptable to the Company, the Company will likely not be able to take advantage of unanticipated opportunities, further develop its products, or continue as a going concern.

The Company is also subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, successful commercialization of product candidates, protection of proprietary technology and compliance with Food and Drug Administration regulations.

Impairment of Assets

In February 2010 the Company requested that a patent valuation of its patent assts be performed. The valuation determined the value of the patents is no greater than $10,000. As a result, the Company recorded an impairment loss of $409,280 on this asset. The impairment loss was recorded because the Company believes that it is improbable that it will receive approval from the FDA prior to the expiration of the patents in 2014.

F-7

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATIONS

The following discussion and analysis should be read in conjunction with the Financial Statements and notes thereto appearing elsewhere in this quarterly report on Form 10-Q /A .

Certain statements contained herein may constitute forward-looking statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, Tetragenex Pharmaceuticals, Inc.’s (referred to herein as “Tetragenex,” “we,” “our,” or

us”) ability to obtain financing in the short term, risks associated with our clinical trials, our lack of revenue, and our inability to maintain working capital requirements to fund future operations.

You should read the following discussion and analysis in conjunction with the Financial Statements and Notes attached thereto, and the other financial information appearing elsewhere in this Annual Report

OVERVIEW

We are headquartered in Englewood Cliffs, New Jersey, and we were a wholly owned subsidiary of Innapharma, Inc. (“Innapharma”). Innapharma was founded in 1989 in the State of Delaware as a biotechnology company that has discovered and intends to commercialize proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases (“CNS”).

We have a platform of peptides which have shown activity in the treatment of CNS diseases. Nemifitide, our lead compound, was initially entered into human clinical trials in the late 1990’s. Over 12 clinical trials have been conducted with Nemifitide for various types of depression. We believe that Nemifitide is active in refractory or treatment resistant patients. Treatment resistant patients are typically difficult to treat and normally don’t respond to other central nervous system treatments. Nemifitide has shown a rapid and robust onset of action with lasting benefits of approximately four months following treatment. Nemifitide is well tolerated, without any current evidence of significant side effects as compared to the drugs that are used in the treatment of major depressive disorder currently.

As a result of the difficult economic environment, we believe that it is improbable that we will be able to obtain FDA approval for Nemifitide to be administered in the United States prior to the expiration of our patents in 2014. Therefore, we are seeking regulatory approval to sell Nemifitide in several Central American, Eastern European and Caribbean countries based on its current data. Patients will then be treated at centers located in those countries.

STATE OF NEW JERSEY DEVELOPMENT PLAN

Since 2003, we have sold a portion of our tax losses through a development program sponsored by the State of New Jersey (the “Development Plan”). We applied to participate in the Development Plan in 2009 and have been approved. In January 2010 we received $133,079 as part of this program. However, we do not meet the Development Plan’s criteria for participation in 2010 and as a result have not submitted our application.

LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2010 we had approximately $95,000 in cash and have a core burn rate of approximately $7,000 per month. As of August 13, 2010, we have approximately $75,000 in working capital and have a core burn rate of approximately $7,000 per month. We believe that $75,000 is sufficient for 11 months of working capital (excluding the $369,374 in debt that is due).

The $75,000 will be used primarily for operating expenses and costs associated with obtaining registration for Nemifitide abroad. Additional capital will be needed to gain approval for Nemifitide in Central American, Eastern European and Carribean countries and to establish clinics in those countries. We are considering all strategic options which may provide working capital to fund our continuing business operations including equity offerings and debt financings; however, we can offer no assurance that we will be successful in identifying, obtaining or negotiating financing terms. If adequate funds are not available or are not available on terms acceptable to us, we will likely not be able to take advantage of unanticipated opportunities, further develop our products, or continue as a going concern.

As of August 13, 2010, we have aggregate liabilities of $3,753,524 consisting of bridge loans plus interest, accrued employee and director salaries as well as accounts payable from day to day operations .

RESULTS OF OPERATIONS

The Three Months ended June 30, 2010 Compared to the Three Months ended June 30, 2009

Revenue – We had no revenue from any source for the three months ending June 30, 2010 and 2009.

Compensation Expense – Compensation expense decreased by $613,679 to $162,962 for the three months ended June 30, 2010, as compared to $776,641 for the three months ended June 30, 2009. This decrease was attributable to our accruing fewer officers’ and directors’ salaries.

Professional Fees – Professional fees decreased by $30,586 to $279 for the three months ended June 30, 2010, as compared to $30,865 for the three months ended June 30, 2009. This decrease was attributable to the deferral of professional fees.

Insurance Expense – Insurance costs decreased by $9,265 to $(4,059) for the three months ending June 30, 2010, as compared to $5,206 for the three months ending June 30, 2009. This decrease was attributable to restructuring of our insurance, our prepayment of certain premiums in the fourth quarter of 2009 and our receiving a refund from a cancelled insurance policy.

Directors Fees – Director’s Fees expenses decreased by $88,016 to $23,666 for the three months ending June 30, 2010, as compared to $111,682 for the three months ended June 30, 2009. This decrease was attributable to fewer accruals of directors’ fees.

Travel and Entertainment Fee – Travel and Entertainment expenses decreased by $3,932 to $5,552 for the three months ending June 30, 2010, as compared to $9,484 for the three months ended June 30, 2009. This decrease was attributable to our having prepaid a car lease, which was required by the leasing company upon our filing for bankruptcy in 2009.

Interest Expense Fee – Interest expense fees decreased by $25,669 to $13,531 for the three months ending June 30, 2010, as compared to $40,202 for the three months ended June 30, 2009. This decrease was attributable to the settlement of the note we had outstanding to KBC Private Equity NV in January 2010 and no further interest being accrued.

Amortization Expense – Amortization expense fees decreased by $17,262 to $787 for the three months ending June 30, 2010, as compared to $18,047 for the three months ended June 30, 2009. This decrease was attributable to our impairment of loss on our patents.

Rent and Occupancy – Rent and occupancy fees increased by $5,497 to $12,869 for the three months ending June 30, 2010, as compared to $7,372 for the three months ended June 30, 2009. This increase was attributable to an increase in rent at the company’s headquarters, which will be payable in stock.

Employee Benefits –Employee benefit expenses decreased by $5,910 to $6,608 for the three months ending June 30, 2010, as compared to $12,518 for the three months ended June 30, 2009. This decrease was attributable to the changing of our insurance plan.

The Six Months ended June 30, 2010 Compared to the Six Months ended June 30, 2009

Revenue – We had no revenue from any source for the six months ending June 30, 2010 and 2009.

Compensation Expense – Compensation expense decreased by $489,144 to $331,853 for the six months ended June 30, 2010, as compared to $820,997 for the six months ended June 30, 2009. This decrease was attributable to our accruing fewer officers’ and directors’ salaries.

Professional Fees – Professional fees decreased by $35,435 to $10,430 for the six months ended June 30, 2010, as compared to $45,865 for the six months ended June 30, 2009. This decrease was attributable to the deferral of professional fees.

Insurance Expense – Insurance costs decreased by $25,478 to $(2,925) for the six months ending June 30, 2010, as compared to $22,552 for the six months ending June 30, 2009. This decrease was attributable to restructuring our insurance, our prepayment of some premiums in the fourth quarter of 2009 and our receiving a refund from a cancelled insurance policy.

Directors Fees – Director’s Fees expenses decreased by $64,870 to $46,811 for the six months ending June 30, 2010, as compared to $111,682 for the six months ended June 30, 2009. This decrease was attributable to fewer accruals of directors’ fees.

Travel and Entertainment Fee – Travel and Entertainment expenses decreased by $17,119 to $7,128 for the six months ending June 30, 2010, as compared to $24,247 for the six months ended June 30, 2009. This decrease was attributable to our having prepaid a car lease, which was required by the leasing company upon our filing for bankruptcy in 2009.

Interest Expense Fee – Interest expense fees decreased by $33,147 to $32,007 for the six months ending June 30, 2010, as compared to $65,154 for the six months ended June 30, 2009. This decrease was attributable to the settlement of the note we had outstanding to KBC Private Equity NV in January 2010 and no further interest being accrued.

Amortization Expense – Amortization expense fees decreased by $34,138 to $1,570 for the six months ending June 30, 2010, as compared to $35,708 for the six months ended June 30, 2009. This decrease was attributable to our impairment of loss on our patents.

Rent and Occupancy – Rent and occupancy fees increased by $6,640 to $25,421 for the six months ending June 30, 2010, as compared to $18,781 for the six months ended June 30, 2009. This increase was attributable to an increase in rent at our headquarters, which will be payable in stock.

Employee Benefits –Employee benefit expenses decreased by $7,264 to $17,772 for the six months ending June 30, 2010, as compared to $25,036 for the six months ended June 30, 2009. This decrease was attributable to the changing of our insurance plan.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

(A) EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We maintain a system of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that is designed to ensure that information required to be disclosed in our Securities and Exchange Commission (the “SEC”) reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and to ensure that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers (one of whom currently also serves as our Principal Financial Officer), as appropriate, to allow timely decisions regarding required disclosure. Management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures, which, by their nature, can provide only reasonable assurance regarding management’s control objectives.

Management, with the participation of our Co-Chief Executive Officers (one of whom currently also serves as our Principal Financial Officer), has evaluated the effectiveness of our disclosure controls and procedures, as of the end of the period covered by this Quarterly Report on Form 10-Q /A . Based upon this evaluation, management concluded that our disclosure controls and procedures were not effective as of the end of the fiscal quarter. In making this evaluation, the Co-Chief Executive Officers considered, among other matters, the material weakness in our internal control over financial reporting described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, filed with the SEC on April 15, 2010.

There have been no significant changes in our internal controls over financial reporting during the quarter ended June 30, 2010 that have altered our conclusion as to the ineffectiveness of such controls.

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the normal course of business, there may be various legal actions and proceedings pending which seek damages against us. As of June 30, 2010, we were not party to any material legal proceedings, nor to our knowledge, are there any proceedings threatened against us.

ITEM 1A. RISK FACTORS

Our auditors have expressed doubt regarding our ability to continue as a going concern.

The report of our independent registered public accounting firm on our consolidated financial statements for the fiscal year ended December 31, 2009 contains an explanatory paragraph regarding our ability to continue as a going concern based upon our history of net losses. We have had recurring annual operating losses since our fiscal inception. We expect that such losses will continue at least through our fiscal year ending December 31, 2010.

We cannot offer assurances that any of the options that we are considering to provide us with working capital will occur or be successful.

We are considering a variety of strategic options to provide us with working capital. These options include equity offerings, debt financings, identifying a licensing partner to continue our development of Nemifitide, and obtaining regulatory approval to sell Nemifitide in foreign jurisdictions. However, there can be no assurance that we will be successful in negotiating or concluding any of these transactions. If we are unable to consummate one or more of these transactions, and if adequate funds are not available to us or are not available on acceptable terms, we will likely not be able to continue as a going concern.

We may not be able to continue our operations without additional funding.

As of August 13, 2010, we had cash and cash equivalents of approximately $75,000. We will require additional capital to complete our business strategy, which we may obtain through issuance of debt and/or equity. Such financing, may not be forthcoming. As widely reported, the domestic financial markets have been extremely volatile in recent months. If such conditions and constraints continue, we may not be able to acquire additional funds either through credit markets or through equity markets. Even if additional financing is available, it may not be available on terms we find favorable. Failure to secure the needed additional financing will have an adverse effect on our ability to remain in business.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The foregoing issuances of securities were effected in reliance upon Section 4(2) of the Securities Act of 1933, as amended.

ITEM 3. DEFAULTS ON SENIOR SECURITIES

None.

ITEM 4. REMOVED AND RESERVED

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit No.	Description
31.1	Certification of Co-Chief Operating Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of the Co-Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of Section 13(a) and 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TETRAGENEX PHARMACEUTICALS, INC.

September 15 , 2010	/s/Martin Schacker
	Martin Schacker Co-Chief Executive Officer and Principal Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
31.1	Certification of Co-Chief Operating Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of the Co-Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, Section 906 of the Sarbanes-Oxley Act of 2002

TETRAGENEX PHARMACEUTICALS, INC. 10-Q/A